guest ::
| Home > Publications database > Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics. > print |
| Home > Publications database > Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics. > print |
| 001 | 289450 | ||
| 005 | 20250819104912.0 | ||
| 024 | 7 | _ | |a 10.1016/S2468-1253(23)00357-6 |2 doi |
| 024 | 7 | _ | |a pmid:38604200 |2 pmid |
| 024 | 7 | _ | |a 2468-1253 |2 ISSN |
| 024 | 7 | _ | |a 2468-1156 |2 ISSN |
| 024 | 7 | _ | |a altmetric:161675932 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-00772 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Porcari, Serena |b 0 |
| 245 | _ | _ | |a Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics. |
| 260 | _ | _ | |a London |c 2024 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1713269084_20785 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The gut microbiome is acknowledged as a key determinant of human health, and technological progress in the past two decades has enabled the deciphering of its composition and functions and its role in human disorders. Therefore, manipulation of the gut microbiome has emerged as a promising therapeutic option for communicable and non-communicable disorders. Full exploitation of current therapeutic microbiome modulators (including probiotics, prebiotics, and faecal microbiota transplantation) is hindered by several factors, including poor precision, regulatory and safety issues, and the impossibility of providing reproducible and targeted treatments. Artificial microbiota therapeutics (which include a wide range of products, such as microbiota consortia, bacteriophages, bacterial metabolites, and engineered probiotics) have appeared as an evolution of current microbiota modulators, as they promise safe and reproducible effects, with variable levels of precision via different pathways. We describe the landscape of artificial microbiome therapeutics, from those already on the market to those still in the pipeline, and outline the major challenges for positioning these therapeutics in clinical practice. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Prebiotics |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Microbiota |2 MeSH |
| 650 | _ | 2 | |a Probiotics: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a Prebiotics |2 MeSH |
| 650 | _ | 2 | |a Gastrointestinal Microbiome |2 MeSH |
| 650 | _ | 2 | |a Fecal Microbiota Transplantation |2 MeSH |
| 700 | 1 | _ | |a Fusco, William |b 1 |
| 700 | 1 | _ | |a Spivak, Igor |b 2 |
| 700 | 1 | _ | |a Fiorani, Marcello |b 3 |
| 700 | 1 | _ | |a Gasbarrini, Antonio |b 4 |
| 700 | 1 | _ | |a Elinav, Eran |0 P:(DE-He78)725ad944da4e1ea60389fe9dbbed2c7c |b 5 |u dkfz |
| 700 | 1 | _ | |a Cammarota, Giovanni |b 6 |
| 700 | 1 | _ | |a Ianiro, Gianluca |b 7 |
| 773 | _ | _ | |a 10.1016/S2468-1253(23)00357-6 |g Vol. 9, no. 5, p. 460 - 475 |0 PERI:(DE-600)2874542-5 |n 5 |p 460 - 475 |t The lancet / Gastroenterology & Hepatology |v 9 |y 2024 |x 2468-1253 |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/289450/files/1-s2.0-S2468125323003576-main.pdf |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/289450/files/1-s2.0-S2468125323003576-main.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |o oai:inrepo02.dkfz.de:289450 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)725ad944da4e1ea60389fe9dbbed2c7c |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b LANCET GASTROENTEROL : 2022 |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-24 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-08-24 |
| 915 | _ | _ | |a IF >= 30 |0 StatID:(DE-HGF)9930 |2 StatID |b LANCET GASTROENTEROL : 2022 |d 2023-08-24 |
| 920 | 1 | _ | |0 I:(DE-He78)F220-20160331 |k F220 |l Mikrobiom und Krebs |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)D480-20160331 |k D480 |l Mikrobiom und Krebs |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)F220-20160331 |
| 980 | _ | _ | |a I:(DE-He78)D480-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|